Insights
Insights From Our Experts
Articles
A Matching-Adjusted Indirect Comparison (MAIC) of Guselkumab Versus Risankizumab in Patients With Moderate-to-Severe Plaque Psoriasis
Psoriasis (PsO) patients have multiple biologic treatments to choose from, including the interleukin-23 inhibitors guselkumab and risankizumab. Both have demonstrated superior skin efficacy, as assessed using Psoriasis Area and Severity Index (PASI) scores, in their respective…
Evolving Standards: NICE’s Enhanced RWE Framework for Global Data Transportability
The National Institute for Health and Care Excellence (NICE) has updated its real-world evidence (RWE) framework published in June 2022. The framework guides the planning, conduct and reporting of RWE studies, with the objective of improving…
AI’s Role in Drug Launches, Operations, and Drug Pricing: Q&A with Abid Rahman
Over the past year, AI-powered technology has become more and more commonplace across the pharmaceutical industry. Abid Rahman, senior vice president of innovation at EVERSANA, spoke with Pharmaceutical Executive about some of the various sectors where…
Filling in the Gaps: Predicting Treatment Effects From Surrogate Endpoints
Over the past 15 years, the treatment landscape for first-line metastatic castration-resistant prostate cancer (mCRPC) has undergone significant changes, marked by the approval and investigation of several new therapies. With multiple pharmacological treatments available for first-line…
In-Depth with an Industry Leader: Global Launch Ambitions and Paradigm Shifts
Biotech enterprises, driven by the dual goals of treating a maximum patient population and ensuring a robust return on investment, must strategically navigate the complex landscape of global commercialization. Although the United States remains a crucial…
Empower to Impact: Advocacy Training for Meaningful Change
Posted by
Ryan Clarke, LL.B on July 15, 20247/15/24
Advocacy training is central to empowering advocacy champions, and for EVERSANA’s Advocacy & PR group in Canada, it is at the core of the work that they do. In a recent conversation, Ryan Clarke, LL.B., senior…
EVERSANA Named Global Host and Presenting Sponsor of Frontiers Health 2024, Bringing Innovators Together Across Europe and Beyond to Transform Healthcare
Today EVERSANA, a leading provider of global commercial services to the life sciences industry, is proud to announce that we will be the global host and presenting sponsor for Frontiers Health 2024. The two-day event, which…
Report: Integrated Delivery Network Trends and Engagement Strategies Every Drug Manufacturer Needs to Know
Unlock the full potential of your Integrated Delivery Network (IDN) strategies with EVERSANA’s latest Market Research & Insights Report. Drug manufacturers are engaging with IDNs to address pain points and trends, optimize patient outcomes, and foster…
The Integral Role of Global Indirect Treatment Comparison in Europe’s JCA
Discover the integral role of Global Indirect Treatment Comparison (ITC) Programs in Europe’s Joint Clinical Assessment (JCA) in this insightful piece by EVERSANA. Learn why a global ITC program is not just beneficial but essential for…
Transforming the Future of Pharma Commercialization Through Medical Affairs
The pharmaceutical industry is rapidly evolving, and Medical Affairs is at the forefront of this transformation. As a clinician, it is an exciting time to think about the possibilities and how several emerging factors are…